Takeda Pharmaceutical (TAK) Free Cash Flow Growth (1y) (2019 - 2026)
Takeda Pharmaceutical (TAK) Free Cash Flow Growth (1y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn | 134.35% |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn | 17.21% |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | -37.45% |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 58.76% |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | 97.24% |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 43.69% |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 35.56% |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | - |
| 10 | Alkermes | 8.12 Bn | 7.46 Bn | 397.90 Mn | -0.11% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -37.45% |
| Mar 31, 2026 | 56.40% |
| Dec 31, 2025 | -4.43% |
| Sep 30, 2025 | 28.16% |
| Jun 30, 2025 | 24.40% |
| Mar 31, 2025 | -357.85% |
| Dec 31, 2024 | 115.45% |
| Sep 30, 2024 | 35.13% |
| Jun 30, 2024 | 44.91% |
| Mar 31, 2024 | -151.38% |
| Dec 31, 2023 | -55.07% |
| Sep 30, 2023 | -9.54% |
| Jun 30, 2023 | 3.32% |
| Mar 31, 2023 | -74.31% |
| Dec 31, 2022 | -11.57% |
| Sep 30, 2022 | -24.41% |
| Jun 30, 2022 | -45.62% |
| Mar 31, 2022 | -30.15% |
| Dec 31, 2021 | 41.98% |
| Sep 30, 2021 | -6.92% |